Thalidomide for the Treatment of Esophageal Aphthous Ulcers in Patients with Human Immunodeficiency Virus Infection
Autor: | David A. Wohl, John L. Fahey, Miriam Chernoff, Nesli Basgoz, Albert W. Wu, Cecilia M. Shikuma, Laurie A. MacPhail, Thomas M. Hooton, Beverly E. Sha, David M. Simpson, Jeffrey M. Jacobson, Lawrence Fox, Carol B. Trapnell, John Spritzler, J. Brooks Jackson |
---|---|
Rok vydání: | 1999 |
Předmět: |
medicine.medical_specialty
Chemotherapy biology business.industry Esophageal disease medicine.medical_treatment Odds ratio Placebo medicine.disease biology.organism_classification Gastroenterology Surgery Thalidomide stomatognathic diseases Infectious Diseases stomatognathic system Acquired immunodeficiency syndrome (AIDS) Immunopathology Internal medicine medicine Immunology and Allergy business Sida medicine.drug |
Zdroj: | The Journal of Infectious Diseases. 180:61-67 |
ISSN: | 1537-6613 0022-1899 |
DOI: | 10.1086/314834 |
Popis: | Background In patients with advanced human immunodeficiency virus (HIV) infection, aphthous ulceration of the mouth and oropharynx can become extensive and debilitating. Preliminary reports suggest that thalidomide may promote the healing of oral aphthous ulcers. Methods We performed a double-blind, randomized, placebo-controlled study of thalidomide as therapy for oral aphthous ulcers in HIV-infected patients. The patients received a four-week course of either 200 mg of thalidomide or placebo orally once per day. They were evaluated weekly for the condition of the ulcers, their quality of life, and evidence of toxicity. Assays were performed for plasma tumor necrosis factor α (TNF-α), soluble TNF-α receptors, and HIV RNA. Results Sixteen of 29 patients in the thalidomide group (55 percent) had complete healing of their aphthous ulcers after four weeks, as compared with only 2 of 28 patients in the placebo group (7 percent; odds ratio, 15; 95 percent confidence interval after adjustment for group sequenti... |
Databáze: | OpenAIRE |
Externí odkaz: |